Advertisement

Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review

Published:February 05, 2019DOI:https://doi.org/10.1016/j.diabres.2019.01.033

      Highlights

      • Cigarette smoking contributes to the macro- and micro-vascular complications of DM.
      • Conventional smoking cessation pharmacotherapy may be less effective in DM smokers.
      • GLP-1 RAs could present a potential treatment for smoking and DM comorbidity.

      Abstract

      Tobacco use disorder (TUD), in particular cigarette smoking, contributes significantly to the macro- and micro-vascular complications of type 2 diabetes mellitus (DM). Persons with DM who regularly use tobacco products are twice as likely to experience mortality and negative health outcomes. Despite these risks, TUD remains prevalent in persons with DM. The objective of this integrative review is to summarize the relationship between TUD and DM based on epidemiological and preclinical biological evidence. We conclude with a review of the literature on the glucagon-like peptide-1 (GLP-1) as a potential treatment target for addressing comorbid TUD in smokers with DM.

      Keywords

      Abbreviations:

      CO (carbon monoxide), CPA (conditioned place aversion), CPP (conditioned place preference), CVD (cardiovascular disease), CAD (coronary artery disease), EPM (elevated plus maze), eNOS (endothelial nitric oxide synthase), XR (extended release), GI (gastrointestinal), GLP-1 (glucagon-like peptide-1), HbA1C (glycosylated hemoglobin), HFD (high fat diet), IL-6 (interleukin 6), IPN (interpeduncular nucleus), MHb (medial habenular), NRT (nicotine replacement therapy), NAc (nucleus accumbens), NTS (nucleus tractus solitarius), OR (odds ratio), PPG (preproglucagon), RA (receptor agonist), RD (regular diet), RR (relative risk), STZ (streptozotocin), DM (type 2 diabetes mellitus), TUD (tobacco use disorder), TNF-α (tumor necrosis factor alpha), VTA (ventral tegmental area)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. The health consequences of smoking-50 years of progress: a report of the surgeon general. Atlanta, GA; 2014.

        • Buse J.B.
        • Bigger J.T.
        • Byington R.P.
        • Cooper L.S.
        • Cushman W.C.
        • Friedewald W.T.
        • et al.
        Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
        Am J Cardiol. 2007; 99: 21i-33i
        • Seuring T.
        • Archangelidi O.
        • Suhrcke M.
        The economic costs of type 2 diabetes: a global systematic review.
        Pharmacoeconomics. 2015; 33: 811-831
      2. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–46.

        • Fagard R.H.
        • Nilsson P.M.
        Smoking and diabetes – the double health hazard!.
        Prim Care Diabetes. 2009; 3: 205-209
        • Canoy D.
        • Wareham N.
        • Luben R.
        • Welch A.
        • Bingham S.
        • Day N.
        • et al.
        Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study.
        Obesity Res. 2005; 13: 1466-1475
        • Hong J.W.
        • Ku C.R.
        • Noh J.H.
        • Ko K.S.
        • Rhee B.D.
        • Kim D.J.
        association between self-reported smoking and hemoglobin A1c in a Korean population without diabetes: the 2011–2012 Korean National Health and Nutrition Examination Survey.
        PloS One. 2015; 10: e0126746
        • Bajaj M.
        Nicotine and insulin resistance: when the smoke clears.
        Diabetes. 2012; 61: 3078-3080
        • Sargeant L.A.
        • Khaw K.T.
        • Bingham S.
        • Day N.E.
        • Luben R.N.
        • Oakes S.
        • et al.
        Cigarette smoking and glycaemia: the EPIC-Norfolk Study. European Prospective Investigation into Cancer.
        Int J Epidemiol. 2001; 30: 547-554
        • Gordon P.
        • Flanagan P.
        Smoking: a risk factor for vascular disease.
        J Vasc Nurs: Off Publ Soc Peripheral Vasc Nurs. 2016; 34: 79-86
        • Martin-Timon I.
        • Sevillano-Collantes C.
        • Segura-Galindo A.
        • Del Canizo-Gomez F.J.
        Type 2 diabetes and cardiovascular disease: have all risk factors the same strength?.
        World J Diabetes. 2014; 5: 444-470
        • Qin R.
        • Chen T.
        • Lou Q.
        • Yu D.
        Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies.
        Int J Cardiol. 2013; 167: 342-350
        • Sliwinska-Mosson M.
        • Milnerowicz S.
        • Nabzdyk S.
        • Kokot I.
        • Nowak M.
        • Milnerowicz H.
        The effect of smoking on endothelin-1 in patients with chronic pancreatitis.
        Appl Immunohistochem Mol Morphol: AIMM. 2015; 23: 288-296
        • McEvoy J.W.
        • Nasir K.
        • DeFilippis A.P.
        • Lima J.A.
        • Bluemke D.A.
        • Hundley W.G.
        • et al.
        Relationship of cigarette smoking with inflammation and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis.
        Arterioscl Thromb Vasc Biol. 2015; 35: 1002-1010
        • Harjutsalo V.
        • Groop P.H.
        Epidemiology and risk factors for diabetic kidney disease.
        Adv Chronic Kidney Dis. 2014; 21: 260-266
        • Cignarelli M.
        • Lamacchia O.
        • Di Paolo S.
        • Gesualdo L.
        Cigarette smoking and kidney dysfunction in diabetes mellitus.
        J Nephrol. 2008; 21: 180-189
        • Biesenbach G.
        • Grafinger P.
        • Janko O.
        • Zazgornik J.
        Influence of cigarette-smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients.
        Clin Nephrol. 1997; 48: 146-150
        • Gambaro G.
        • Bax G.
        • Fusaro M.
        • Normanno M.
        • Manani S.M.
        • Zanella M.
        • et al.
        Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus.
        Diabetes Nutr Metab. 2001; 14: 337-342
        • Ritz E.
        • Ogata H.
        • Orth S.R.
        Smoking: a factor promoting onset and progression of diabetic nephropathy.
        Diabetes Metab. 2000; 26: 54-63
        • Kong C.
        • Nimmo L.
        • Elatrozy T.
        • Anyaoku V.
        • Hughes C.
        • Robinson S.
        • et al.
        Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes.
        Atherosclerosis. 2001; 156: 373-378
        • Meigs J.B.
        • Singer D.E.
        • Sullivan L.M.
        • Dukes K.A.
        • D'Agostino R.B.
        • Nathan D.M.
        • et al.
        Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team.
        Am J Med. 1997; 102: 38-47
        • Eliasson B.
        Cigarette smoking and diabetes.
        Prog Cardiovasc Dis. 2003; 45: 405-413
        • Fuller J.H.
        • Stevens L.K.
        • Wang S.L.
        Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes.
        Diabetologia. 2001; 44: S54-S64
        • Tuomilehto J.
        • Rastenyte D.
        • Jousilahti P.
        • Sarti C.
        • Vartiainen E.
        Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population.
        Stroke. 1996; 27: 210-215
        • Kothari V.
        • Stevens R.J.
        • Adler A.I.
        • Stratton I.M.
        • Manley S.E.
        • Neil H.A.
        • et al.
        UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.
        Stroke. 2002; 33: 1776-1781
        • Scemama O.
        • Hamo-Tchatchouang E.
        • Le Faou A.L.
        • Altman J.J.
        Difficulties of smoking cessation in diabetic inpatients benefiting from a systematic consultation to help them to give up smoking.
        Diabetes Metab. 2006; 32: 435-441
        • Tonstad S.
        Cigarette smoking, smoking cessation, and diabetes.
        Diabetes Res Clin Pract. 2009; 85: 4-13
        • Gilmer T.P.
        • O'Connor P.J.
        • Rush W.A.
        • Crain A.L.
        • Whitebird R.R.
        • Hanson A.M.
        • et al.
        Predictors of health care costs in adults with diabetes.
        Diabetes Care. 2005; 28: 59-64
        • Willi C.
        • Bodenmann P.
        • Ghali W.A.
        • Faris P.D.
        • Cornuz J.
        Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis.
        JAMA. 2007; 298: 2654-2664
      3. National Center for Chronic Disease P, Health Promotion Office on S. Health: reports of the surgeon general; the health consequences of smoking-50 years of progress: a report of the surgeon general. Atlanta (GA), Centers for Disease Control and Prevention (US); 2014.

        • Pan A.
        • Wang Y.
        • Talaei M.
        • Hu F.B.
        • Wu T.
        Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis.
        Lancet Diabetes Endocrinol. 2015; 3: 958-967
        • Ding E.L.
        • Hu F.B.
        Smoking and type 2 diabetes: underrecognized risks and disease burden.
        JAMA. 2007; 298: 2675-2676
        • Aeschbacher S.
        • Schoen T.
        • Clair C.
        • Schillinger P.
        • Schonenberger S.
        • Risch M.
        • et al.
        Association of smoking and nicotine dependence with pre-diabetes in young and healthy adults.
        Swiss Med Wkly. 2014; 144: w14019
        • Fan A.Z.
        • Rock V.
        • Zhang X.
        • Li Y.
        • Elam-Evans L.
        • Balluz L.
        Trends in cigarette smoking rates and quit attempts among adults with and without diagnosed diabetes, United States, 2001–2010.
        Prev Chronic Dis. 2013; 10: E160
        • Stanton C.A.
        • Keith D.R.
        • Gaalema D.E.
        • Bunn J.Y.
        • Doogan N.J.
        • Redner R.
        • et al.
        Trends in tobacco use among US adults with chronic health conditions: National Survey on Drug Use and Health 2005–2013.
        Prev Med. 2016; 92: 160-168
        • O'Dell L.E.
        • Nazarian A.
        Enhanced vulnerability to tobacco use in persons with diabetes: a behavioral and neurobiological framework.
        Prog Neuropsychopharmacol Biol Psychiatry. 2016; 65: 288-296
        • Richardson J.R.
        • Pipkin J.A.
        • O'Dell L.E.
        • Nazarian A.
        Insulin resistant rats display enhanced rewarding effects of nicotine.
        Drug Alcohol Depend. 2014; 140: 205-207
        • Pipkin J.A.
        • Cruz B.
        • Flores R.J.
        • Hinojosa C.A.
        • Carcoba L.M.
        • Ibarra M.
        • et al.
        Both nicotine reward and withdrawal are enhanced in a rodent model of diabetes.
        Psychopharmacology (Berl). 2017; 234: 1615-1622
        • Cunningham E.
        Is weight gain inevitable after smoking cessation?.
        J Acad Nutr Diet. 2013; 113: 180
        • Borrelli B.
        • Mermelstein R.
        The role of weight concern and self-efficacy in smoking cessation and weight gain among smokers in a clinic-based cessation program.
        Addict Behav. 1998; 23: 609-622
        • Pomerleau C.S.
        • Zucker A.N.
        • Stewart A.J.
        Characterizing concerns about post-cessation weight gain: results from a national survey of women smokers.
        Nicotine Tob Res. 2001; 3: 51-60
        • Tonstad S.
        Weight gain does not attenuate cardiovascular benefits of smoking cessation.
        Evid Based Med. 2014; 19: 25
        • Beebe L.A.
        • Bush T.
        Post-cessation weight concerns among women calling a state tobacco quitline.
        Am J Prev Med. 2015; 48: S61-S64
        • Gill G.V.
        • Morgan C.
        • MacFarlane I.A.
        Awareness and use of smoking cessation treatments among diabetic patients.
        Diabet Med. 2005; 22: 658-660
        • Stadler M.
        • Tomann L.
        • Storka A.
        • Wolzt M.
        • Peric S.
        • Bieglmayer C.
        • et al.
        Effects of smoking cessation on beta-cell function, insulin sensitivity, body weight, and appetite.
        Eur J Endocrinol. 2014; 170: 219-1217
        • Hu Y.
        • Zong G.
        • Liu G.
        • Wang M.
        • Rosner B.
        • Pan A.
        • et al.
        Smoking cessation, weight change, type 2 diabetes, and mortality.
        New Engl J Med. 2018; 379: 623-632
        • Sung Y.T.
        • Hsiao C.T.
        • Chang I.J.
        • Lin Y.C.
        • Yueh C.Y.
        Smoking cessation carries a short-term rising risk for newly diagnosed diabetes mellitus independently of weight gain: a 6-year retrospective cohort study.
        J Diabetes Res. 2016; 2016: 3961756
        • Iino K.
        • Iwase M.
        • Tsutsu N.
        • Iida M.
        Smoking cessation and glycaemic control in type 2 diabetic patients.
        Diabetes Obesity Metab. 2004; 6: 181-186
        • Lycett D.
        • Nichols L.
        • Ryan R.
        • Farley A.
        • Roalfe A.
        • Mohammed M.A.
        • et al.
        The association between smoking cessation and glycaemic control in patients with type 2 diabetes: a THIN database cohort study.
        Lancet Diabetes Endocrinol. 2015; 3: 423-430
        • Zhu P.
        • Pan X.F.
        • Sheng L.
        • Chen H.
        • Pan A.
        Cigarette smoking, diabetes, and diabetes complications: call for urgent action.
        Curr Diabetes Rep. 2017; 17: 78
        • Clair C.
        • Rigotti N.A.
        • Porneala B.
        • Fox C.S.
        • D'Agostino R.B.
        • Pencina M.J.
        • et al.
        Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes.
        JAMA. 2013; 309: 1014-1021
        • Luo J.
        • Rossouw J.
        • Margolis K.L.
        Smoking cessation, weight change, and coronary heart disease among postmenopausal women with and without diabetes.
        JAMA. 2013; 310: 94-96
        • Blomster J.I.
        • Woodward M.
        • Zoungas S.
        • Hillis G.S.
        • Harrap S.
        • Neal B.
        • et al.
        The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial.
        BMJ Open. 2016; 6: e009668
        • Al-Delaimy W.K.
        • Manson J.E.
        • Solomon C.G.
        • Kawachi I.
        • Stampfer M.J.
        • Willett W.C.
        • et al.
        Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus.
        Arch Intern Med. 2002; 162: 273-279
        • Pan A.
        • Wang Y.
        • Talaei M.
        • Hu F.B.
        Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review.
        Circulation. 2015; 132: 1795-1804
        • Phisitkul K.
        • Hegazy K.
        • Chuahirun T.
        • Hudson C.
        • Simoni J.
        • Rajab H.
        • et al.
        Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy.
        Am J Med Sci. 2008; 335: 284-291
        • Chuahirun T.
        • Simoni J.
        • Hudson C.
        • Seipel T.
        • Khanna A.
        • Harrist R.B.
        • et al.
        Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes.
        Am J Med Sci. 2004; 327: 57-67
        • Voulgari C.
        • Katsilambros N.
        • Tentolouris N.
        Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study.
        Metab: Clin Exp. 2011; 60: 1456-1464
        • Reid R.D.
        • Malcolm J.
        • Wooding E.
        • Geertsma A.
        • Aitken D.
        • Arbeau D.
        • et al.
        Prospective, cluster-randomized trial to implement the Ottawa model for smoking cessation in diabetes education programs in Ontario, Canada.
        Diabetes Care. 2018; 41: 406-412
        • Eisenberg M.J.
        • Blum L.M.
        • Filion K.B.
        • Rinfret S.
        • Pilote L.
        • Paradis G.
        • et al.
        The efficacy of smoking cessation therapies in cardiac patients: a meta-analysis of randomized controlled trials.
        Can J Cardiol. 2010; 26: 73-79
        • Pires-Yfantouda R.
        • Absalom G.
        • Clemens F.
        Smoking cessation interventions for COPD: a review of the literature.
        Respirat Care. 2013; 58: 1955-1962
        • Nagrebetsky A.
        • Brettell R.
        • Roberts N.
        • Farmer A.
        Smoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trials.
        BMJ Open. 2014; 4: e004107
        • Tonstad S.
        • Lawrence D.
        Varenicline in smokers with diabetes: a pooled analysis of 15 randomized, placebo-controlled studies of varenicline.
        J Diabetes Invest. 2017; 8: 93-100
        • Novak U.
        • Wilks A.
        • Buell G.
        • McEwen S.
        Identical mRNA for preproglucagon in pancreas and gut.
        Eur J Biochem. 1987; 164: 553-558
        • Brubaker P.L.
        • Anini Y.
        Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.
        Can J Physiol Pharmacol. 2003; 81: 1005-1012
        • Holst J.J.
        The physiology of glucagon-like peptide 1.
        Physiol Rev. 2007; 87: 1409-1439
        • Barrera J.G.
        • Jones K.R.
        • Herman J.P.
        • D'Alessio D.A.
        • Woods S.C.
        • Seeley R.J.
        Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function.
        J Neurosci: Off J Soc Neurosci. 2011; 31: 3904-3913
        • Heppner K.M.
        • Perez-Tilve D.
        GLP-1 based therapeutics: simultaneously combating T2DM and obesity.
        Front Neurosci. 2015; 9: 92
        • Nuffer W.
        • Guesnier A.
        • Trujillo J.M.
        A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products.
        Therap Adv Endocrinol Metab. 2018; 9: 69-79
        • Holst J.J.
        • Seino Y.
        GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
        Diabetes Res Clin Pract. 2009; 85: 1-3
        • Skibicka K.P.
        The central GLP-1: implications for food and drug reward.
        Front Neurosci. 2013; 7: 181
        • Holst J.J.
        • Deacon C.F.
        • Vilsboll T.
        • Krarup T.
        • Madsbad S.
        Glucagon-like peptide-1, glucose homeostasis and diabetes.
        Trends Mol Med. 2008; 14: 161-168
        • Meier J.J.
        GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
        Nat Rev Endocrinol. 2012; 8: 728-742
        • Bahtiyar G.
        • Pujals-Kury J.
        • Sacerdote A.
        Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes.
        Curr Diabetes Rep. 2018; 18: 92
        • Bose A.K.
        • Mocanu M.M.
        • Carr R.D.
        • Brand C.L.
        • Yellon D.M.
        Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
        Diabetes. 2005; 54: 146-151
        • Liu H.
        • Dear A.E.
        • Knudsen L.B.
        • Simpson R.W.
        A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.
        J Endocrinol. 2009; 201: 59-66
        • Shiraki A.
        • Oyama J.
        • Komoda H.
        • Asaka M.
        • Komatsu A.
        • Sakuma M.
        • et al.
        The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells.
        Atherosclerosis. 2012; 221: 375-382
        • Richter G.
        • Feddersen O.
        • Wagner U.
        • Barth P.
        • Goke R.
        • Goke B.
        GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery.
        Am J Physiol. 1993; 265: L374-L381
        • Han V.K.
        • Hynes M.A.
        • Jin C.
        • Towle A.C.
        • Lauder J.M.
        • Lund P.K.
        Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain.
        J Neurosci Res. 1986; 16: 97-107
        • Jin S.L.
        • Han V.K.
        • Simmons J.G.
        • Towle A.C.
        • Lauder J.M.
        • Lund P.K.
        Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study.
        J Comp Neurol. 1988; 271: 519-532
        • Larsen P.J.
        • Tang-Christensen M.
        • Holst J.J.
        • Orskov C.
        Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.
        Neuroscience. 1997; 77: 257-270
        • Rinaman L.
        Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure.
        Brain Res. 2010; 1350: 18-34
        • Dossat A.M.
        • Lilly N.
        • Kay K.
        • Williams D.L.
        Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake.
        J Neurosci: Off J Soc Neurosci. 2011; 31: 14453-14457
        • Alhadeff A.L.
        • Rupprecht L.E.
        • Hayes M.R.
        GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake.
        Endocrinology. 2012; 153: 647-658
        • Wise R.A.
        • Bozarth M.A.
        Brain reward circuitry: four circuit elements “wired” in apparent series.
        Brain Res Bull. 1984; 12: 203-208
        • Koob G.F.
        Drugs of abuse: anatomy, pharmacology and function of reward pathways.
        Trends Pharmacol Sci. 1992; 13: 177-184
        • Pannacciulli N.
        • Le D.S.
        • Salbe A.D.
        • Chen K.
        • Reiman E.M.
        • Tataranni P.A.
        • et al.
        Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans.
        NeuroImage. 2007; 35: 511-517
        • Tuesta L.M.
        • Chen Z.
        • Duncan A.
        • Fowler C.D.
        • Ishikawa M.
        • Lee B.R.
        • et al.
        GLP-1 acts on habenular avoidance circuits to control nicotine intake.
        Nature neuroscience. 2017; 20: 708-716
        • Suchankova P.
        • Yan J.
        • Schwandt M.L.
        • Stangl B.L.
        • Caparelli E.C.
        • Momenan R.
        • et al.
        The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.
        Transl Psychiatry. 2015; 5: e583
        • Egecioglu E.
        • Steensland P.
        • Fredriksson I.
        • Feltmann K.
        • Engel J.A.
        • Jerlhag E.
        The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.
        Psychoneuroendocrinology. 2013; 38: 1259-1270
        • Shirazi R.H.
        • Dickson S.L.
        • Skibicka K.P.
        Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward.
        PloS One. 2013; 8: e61965
        • Vallof D.
        • Maccioni P.
        • Colombo G.
        • Mandrapa M.
        • Jornulf J.W.
        • Egecioglu E.
        • et al.
        The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents.
        Addict Biol. 2016; 21: 422-437
        • Sorensen G.
        • Reddy I.A.
        • Weikop P.
        • Graham D.L.
        • Stanwood G.D.
        • Wortwein G.
        • et al.
        The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.
        Physiol Behav. 2015; 149: 262-268
        • Erreger K.
        • Davis A.R.
        • Poe A.M.
        • Greig N.H.
        • Stanwood G.D.
        • Galli A.
        Exendin-4 decreases amphetamine-induced locomotor activity.
        Physiol Behav. 2012; 106: 574-578
        • Tuchscherer R.M.
        • Thompson A.M.
        • Trujillo J.M.
        Semaglutide: the newest once-weekly GLP-1 RA for Type 2 diabetes.
        Ann Pharmacother. 2018; (1060028018784583)
        • Trujillo J.M.
        • Nuffer W.
        • Ellis S.L.
        GLP-1 receptor agonists: a review of head-to-head clinical studies.
        Therap Adv Endocrinol Metab. 2015; 6: 19-28
        • Yu M.
        • Xie J.
        • Fernandez Lando L.
        • Kabul S.
        • Swindle R.W.
        Liraglutide versus exenatide once weekly: persistence, adherence, and early discontinuation.
        Clin Therapeut. 2016; 38: 149-160
        • Sikirica M.V.
        • Martin A.A.
        • Wood R.
        • Leith A.
        • Piercy J.
        • Higgins V.
        Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.
        Diab Metab Syndrome Obesity: Targets Therapy. 2017; 10: 403-412
        • Yammine L.
        • Kosten T.R.
        • Cinciripini P.M.
        • Green C.E.
        • Meininger J.C.
        • Minnix J.A.
        • et al.
        Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
        Medicine. 2018; 97: e9567
        • Bethel M.A.
        • Patel R.A.
        • Merrill P.
        • Lokhnygina Y.
        • Buse J.B.
        • Mentz R.J.
        • et al.
        Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
        Lancet Diabetes Endocrinol. 2018; 6: 105-113
        • Stopponi S.
        • de Guglielmo G.
        • Somaini L.
        • Cippitelli A.
        • Cannella N.
        • Kallupi M.
        • et al.
        Activation of PPARgamma by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.
        Alcohol Clin Exp Res. 2013; 37: 1351-1360
        • de Guglielmo G.
        • Melis M.
        • De Luca M.A.
        • Kallupi M.
        • Li H.W.
        • Niswender K.
        • et al.
        PPARgamma activation attenuates opioid consumption and modulates mesolimbic dopamine transmission.
        Neuropsychopharmacol: Off Publ Am College Neuropsychopharmacol. 2015; 40: 927-937
        • de Guglielmo G.
        • Kallupi M.
        • Scuppa G.
        • Demopulos G.
        • Gaitanaris G.
        • Ciccocioppo R.
        Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents.
        Psychopharmacology. 2017; 234: 223-234
        • Schmitz J.M.
        • Green C.E.
        • Hasan K.M.
        • Vincent J.
        • Suchting R.
        • Weaver M.F.
        • et al.
        PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial.
        Addiction (Abingdon, England). 2017; 112: 1861-1868
        • Jones J.D.
        • Comer S.D.
        • Metz V.E.
        • Manubay J.M.
        • Mogali S.
        • Ciccocioppo R.
        • et al.
        Pioglitazone, a PPARgamma agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.
        Pharmacol Biochem Behav. 2017; 163: 90-100
        • Levin E.D.
        • Johnson J.E.
        • Slade S.
        • Wells C.
        • Cauley M.
        • Petro A.
        • et al.
        Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
        J Pharmacol Exp Therapeutics. 2011; 338: 890-896
        • Higgins G.A.
        • Silenieks L.B.
        • Rossmann A.
        • Rizos Z.
        • Noble K.
        • Soko A.D.
        • et al.
        The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
        Neuropsychopharmacol: Off Publ Am College Neuropsychopharmacol. 2012; 37: 1177-1191
        • Guy E.G.
        • Fisher D.C.
        • Higgins G.A.
        • Fletcher P.J.
        Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats.
        Behav Pharmacol. 2014; 25: 775-783
        • DiPalma D.
        • Rezvani A.H.
        • Willette B.
        • Wells C.
        • Slade S.
        • Hall B.J.
        • et al.
        Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D1 receptor antagonist SCH-23390 or the serotonin 5-HT2C agonist lorcaserin.
        Pharmacol Biochem Behav. 2018; 176: 16-22
        • Shanahan W.R.
        • Rose J.E.
        • Glicklich A.
        • Stubbe S.
        • Sanchez-Kam M.
        Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial.
        Nicotine Tobacco Res: Off J Soc Res Nicotine Tobacco. 2017; 19: 944-951
        • Hurt R.T.
        • Croghan I.T.
        • Schroeder D.R.
        • Hays J.T.
        • Choi D.S.
        • Ebbert J.O.
        Combination varenicline and lorcaserin for tobacco dependence treatment and weight gain prevention in overweight and obese smokers: a pilot study.
        Nicotine Tobacco Res: Off J Soc Res Nicotine Tobacco. 2017; 19: 994-998
        • Hurt R.T.
        • Mundi M.S.
        • Ebbert J.O.
        Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release.
        Diabetes Metab Syndrome Obesity: Targets Therapy. 2018; 11: 469-478